Biocompatible UV-absorbing nanoparticles or microparticles that can be embedded in the skin using techniques such as those used to create a tattoo with tattoo ink. The “tattoo” using the biocompatible UV-absorbing nanoparticles or microparticles provides skin protection against sunburn, photoaging, and skin cancers in a permanent or semi-permanent way, but remain clear in the visible light spectrum, or matched closely to the user's specific skin tone. These particles can be solid uniform UV-absorbers, microencapsulated UV-absorbers, or UV-absorbing material embedded in or coated on solid materials. Long-term sun protection from an invisible (does not change the color of the skin) material, embedded in the skin (dermis layer).

The present invention relates to a compound represented by the following formula (I):

A[B—(C).sub.v].sub.w  (I), wherein A is a photoprotective moiety, B is a linker, C is a functional group, v is an integer from 1 to 2000, and w is an integer from 1 to 6. It also relates to a composition comprising the same and, more particularly, to a cosmetic or a sunscreen composition. It also relates to the use of such compounds in cosmetic and therapeutic applications. The invention also relates to the use of such compounds for reducing photodegradation and/or photoinstability of pharmaceuticals and cosmetics. The invention further relates to a material comprising a support and such a compound adhered to said support.

The invention relates to an improved process for the manufacture of nano-sized organic UV absorbers having a mean particle size distribution (D.sub.v50) determined by light scattering of less than 200 nm.

The present invention relates to the synthesis of new classes of sunscreen agents, the usage of such sunscreen agents to prepare sunscreen formulation materials aiming at reduction of sunscreen agents’ skin penetration. The whole purpose of this invention is to improve the biosafety of sunscreen products via our novel sunscreen materials and formulation technology to reduce or to eliminate skin penetration of sunscreen agents. The technology of this invention can be applied to cosmetics, pharmaceutical or insects’ repellant products.

The present invention relates to sunscreen or daily care compositions comprising (i) an ultraviolet absorber water-dispersed composition comprising (a) micronized tris-biphenyl triazine, and (b) decaglyceryl monolaurate; and (ii) at least one oil soluble UVA filter.

The present invention refers in general to the area of sun care products and relates in particular to a cosmetic or pharmaceutical, in particular dermatological, composition or a homecare product comprising or consisting of a solid UV filter and an effective amount of 1,2-heptanediol and/or 2,3-heptanediol or of a specific alkanediol or a mixture of two or more different specific alkanediols and the use of said compositions as a cosmetic, for personal care, as a pharmaceutical, for animal care or as a homecare product. Additionally, the present invention relates to the use of 1,2-heptanediol and/or 2,3-heptanediol or of a specific alkanediol or a mixture of two or more different specific alkanediols for improving the solubility of a solid UV filter, and/or for improving the availability of a solid UV filter in a cosmetic or pharmaceutical composition or homecare product.

Disclosed are cosmetic or pharmaceutical composition comprising a UV filter combination of (a) an aqueous dispersion of 5,6,5′,6′-tetraphenyl-3,3′-(1,4-Phenylene)bis(1,2,4-Triazine) corresponding to the formula ##STR00001## in particulate form; and (b) the UV filters selected from (b.sub.1) Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine; (b.sub.2) Butyl Methoxydibenzoylmethane; (b.sub.3) Diethylhexyl Butamido Triazone; (b.sub.4) Ethylhexyl Triazone; (b.sub.5) Diethylamino Hydroxy Benzoyl Hexyl Benzoate; (b.sub.6) Ethyhexyl Methoxycinnamate; (b.sub.7) Ethylhexyl Salicylate; (b.sub.8) Homosalate; (b.sub.9) Octocrylene; (b.sub.10) Methylene Bis-Benzotriazolyl Tetramethylbutylphenol; (b.sub.11) Phenylbenzimidazole Sulfonic Acid; (b.sub.12) Titanium Dioxide; (b.sub.13) Tris-Biphenyl Triazine; and (b.sub.14) (2-{4-[2-(4-Diethylamino-2-hydroxy-benzoyl)-benzoyl]-piperazine-1-carbonyl}-phenyl)-(4-diethylamino-2-hydroxy-phenyl)-methanone; (b.sub.15) BBDAPT; Benzoic acid, 4,4′-[[6-[[3-[1,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]-1 disiloxanyl]propyl]amino]-1,3,5-triazine-2,4-diyl]diimino]bis-, dibutyl ester; (b.sub.16) benzylidene malonates; and (b.sub.17) merocyanine derivatives; (b.sub.18) Bis(butylbenzoate) diaminotriazine aminopropylsiloxane; (b.sub.19) Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine) encapsulated in a polymer matrix; (b.sub.20) 2-(2H-Benzotriazol-2-yl)-6-[(2-ethylhexyloxy)methyl]-4-methylphenol; and (b.sub.21) 2-Propenoic acid, 3-(4-methoxyphenyl)-, 2-methylphenyl ester.

Provided are compounds of formula (Ia), (Ib) and (IIa), and pharmaceutically acceptable salts thereof. Additionally provided are compositions and pharmaceutical compositions comprising the compounds, therapeutic methods using same for modulating (e.g., inhibiting) CREB binding protein (CBP)/β-catenin mediated signaling in treating a condition, disease or disorder (e.g., fibrosis, cancer, neurological conditions, metabolic disorders (e.g., diabetes, etc.), and skin conditions (dermatitis, psoriasis, scarring, alopecia, etc.) mediated by aberrant CBP/β-catenin signaling, and cosmetic methods for treating skin conditions (e.g., aging, etc.). Additionally, provided are methods for enhancing vaccine efficacy using the compounds and compositions. Further provided are methods for efficiently synthesizing a clinical grade drug, comprising use, in a penultimate, or last reaction step under GMP conditions, of an intermediate 2-propynyl-compound to form a clinical grade isoxazole derivative (e.g., via 3+2 cycloaddition).

The present invention relates to a topical preparation comprising a UV filter combination of certain microfine zinc oxide, 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine (INCI: Bis-Ethylhexyloxyphenol methoxyphenyl Triazine), 2-phenylbenzimidazole-5-sulfonic acid and/or one or more salts thereof and 4,4′-((6((4 (((1,1-dimethylethyl)amino)carbonyl)phenyl)-amino)-1,3,5-triazine-2,4-diyl)diimino)bis(2-ethylhexyl)benzoate (INCI: Diethylhexyl butamido triazone).

The present invention relates to a sunscreen formulation comprising at least one of the UV filters (A) selected from (a) triazine derivatives; (b) cinnamic acid derivatives; (c) bis-resorcinyl triazines; (f) benzimidazole derivatives; (i.sub.5) 4-Methylbenzylidene Camphor; (h) benzoyl piperazine derivatives; (j) benzoxazole derivatives; (k) diarylbutadiene derivatives; (I) phenyl benzotriazole derivatives; (n) benzylidene malonates; (o.sub.3) TEA-Salicylate; (r) imidazoline derivatives; (u) inorganic UV filters selected from metal oxides; (v) naphthalates; and (w) merocyanine derivatives; and optionally comprising at least one of the UV filters (B) selected from (d) aminobenzophenone derivatives; (e) dibenzoylmethane derivatives; (g) β,β-Diphenylacrylate derivatives; (i.sub.5) camphor derivatives different from; (o.sub.3) salicylate derivatives different from; (p) anthranilate derivatives; and (s) benzalmalonate derivatives; wherein the ratio R of the effective irradiance for previtamin D.sub.3 formation E.sub.pvd to the effective irradiance for erythema formation E.sub.er on the skin is at least 1.8, for increasing the transmittance of UV radiation on human skin for the production of cholecalciferol (previtamin D.sub.3) and simultaneously for the use in a method for protecting the human skin against UV radiation when exposed to the sun, which method comprises applying said sunscreen formulation to the skin.